B. Riley analyst Mayank Mamtani raised the firm’s price target on Cytokinetics (CYTK) to $90 from $80 and keeps a Buy rating on the shares. Cytokinetics is positioned for continued strong equity outperformance, driven by the anticipated first FDA approval of aficamten for obstructive hypertrophic cardiomyopathy and a transformative revenue ramp in 1H26, supported by the upcoming Phase 3 ACACIA nHCM readout differentiating it from Bristol Myers’ (BMY) Camzyos, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics presents additional data from MAPLE-HCM
- Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval
- Private Markets: Anthropic projects $70B in revenue in 2028
- Cytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims
- Cytokinetics’ Earnings Call: Progress and Challenges